Baclofen in the treatment of spasticity.
Baclofendagger (Lioresal), a derivative of gamma-aminobutyric acid, was introduced in 1966 as a possible treatment for spasticity due to corticospinal tract lesions. Preliminary studies suggested that it may be more effective than other spasmolytic agents currently available, and a double-blind controlled trial in a group of 23 patients against placebo has shown it to be significantly more effective.
D000328:Adult; D000613:Aminobutyrates / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004576:Electromyography; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000150:complications; D009128:Muscle Spasticity / Q000188:drug therapy*; D009325:Nausea / Q000139:chemically induced; D010243:Paralysis / Q000209:etiology; D013118:Spinal Cord Diseases / Q000150:complications; D014717:Vertigo / Q000139:chemically induced
D000613:Aminobutyrates